These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9661908)

  • 1. The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer.
    Naitoh J; Witte O; Belldegrun A
    Cancer Res; 1998 Jul; 58(13):2895-900. PubMed ID: 9661908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on: "Satisfaction with information used to choose prostate cancer treatment." Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. H. Lee Moffitt Cancer Center, Tampa, Florida; Department of Urology, Emory University, Atlanta, Georgia; Department of Urology, University of Michigan, Ann Arbor, Michigan; Department of Psychiatry and Public Health Institute, University of California-San Francisco, California; Institute for Public Policy and Social Research, Michigan State University, Lansing, Michigan; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; Department of Urology and Department of Health Policy and Management, University of California-Los Angeles, Los Angeles, California; Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.: J Urol 2014;191(5):1265-71. doi:10.1016/j.juro.2013.12.008. [Epub 2013 Dec 12].
    Brent H
    Urol Oncol; 2016 May; 34(5):247-8. PubMed ID: 25990613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of prostate cancer.
    Cress AE; Mohla S
    Cancer Biol Ther; 2004 Oct; 3(10):1028-30. PubMed ID: 15539935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions.
    Pantuck AJ; Zisman A; Belldegrun AS
    World J Urol; 2000 Apr; 18(2):143-7. PubMed ID: 10854150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Roychowdhury S; Goswami S; Ippolito JE; Priceman SJ; Pritchard CC; Sfanos KS; Subudhi SK; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Feb; 77(2):123-144. PubMed ID: 27679977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
    Hsieh CL; Chung LW
    Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Cheng HH; Abida W; Ellis L; Harshman LC; Spratt DE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2017 Nov; 77(15):1478-1488. PubMed ID: 28925066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in preclinical investigation of prostate cancer gene therapy.
    Figueiredo ML; Kao C; Wu L
    Mol Ther; 2007 Jun; 15(6):1053-64. PubMed ID: 17457317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Hawley JE; Adelaiye-Ogala R; Calais J; Nappi L; Parikh R; Seibert TM; Wasmuth EV; Wei XX; Pienta KJ; Soule HR
    Prostate; 2023 Feb; 83(3):207-226. PubMed ID: 36443902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
    Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different approaches of gene therapy used in prostate cancer.
    Ghosh A
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(1):103-11. PubMed ID: 16171569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Den RB; Carlo MI; de Leeuw R; Hope TA; Karzai F; McKay RR; Salami SS; Simons JW; Pienta KJ; Soule HR
    Prostate; 2019 Feb; 79(3):244-258. PubMed ID: 30381857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for gene therapy in human prostate cancer.
    Ficazzola MA; Taneja SS
    Mol Med Today; 1998 Nov; 4(11):494-504. PubMed ID: 9857369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metastatic hormone refractory prostate cancer: new treatment horizon].
    Keizman D; Maimon N; Gottfried M
    Harefuah; 2012 Sep; 151(9):545-9, 555, 554. PubMed ID: 23367751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.